Table 13.6a
Immunosuppression Use for Induction, 1996 to 2005
Recipients with Heart-Lung Transplants

	Year of Transplant									
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005
Transplants	39	62	47	51	48	27	33	29	39	33
With Immunosuppression Info	35	58	45	50	48	26	33	28	37	31
Induction Drugs										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	28.6%	25.9%	20.0%	16.0%	29.2%	26.9%	15.2%	3.6%	13.5%	12.9%
OKT3	8.6%	6.9%	6.7%	10.0%	6.3%	0.0%	6.1%	3.6%	2.7%	3.2%
Thymoglobulin	0.0%	0.0%	0.0%	4.0%	4.2%	11.5%	3.0%	10.7%	13.5%	3.2%
Zenapax	0.0%	0.0%	0.0%	4.0%	12.5%	7.7%	15.2%	7.1%	18.9%	12.9%
Simulect	0.0%	0.0%	0.0%	0.0%	4.2%	30.8%	18.2%	17.9%	10.8%	25.8%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	5.4%	9.7%
No Induction Drugs Recorded	65.7%	70.7%	75.6%	66.0%	47.9%	26.9%	42.4%	57.1%	40.5%	35.5%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.